What is Allergy Plus?
Allergy Plus operates at the intersection of primary care and specialized diagnostic services. By providing a turnkey solution for medical practices, the company enables providers to incorporate advanced testing and procedures directly into routine patient visits. This model not only enhances the continuity of care but also serves as a robust revenue-generation engine for primary care facilities. By streamlining the delivery of state-of-the-art diagnostic tools, Allergy Plus effectively removes the operational friction typically associated with expanding service offerings in a clinical setting, thereby positioning itself as an essential partner for modern healthcare practices seeking to optimize their service portfolios.
How much funding has Allergy Plus raised?
Allergy Plus has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Allergy Plus
PPP
Public-Private Partnership
What's next for Allergy Plus?
With this latest infusion of capital, Allergy Plus is poised to scale its operational footprint and deepen its integration within the primary care ecosystem. The strategic focus will likely shift toward expanding its diagnostic catalog and enhancing the technological infrastructure that supports seamless procedure implementation. As the company moves into this late-stage growth phase, the emphasis will remain on scaling its partnership network and solidifying its role as a critical infrastructure provider for outpatient clinics. By leveraging its recent financing, Allergy Plus aims to set a new standard for how diagnostic services are delivered, ensuring that primary care providers can offer comprehensive, high-value care without compromising operational efficiency or patient convenience.
See full Allergy Plus company page
